$BXRX News
Last published 3y ago
- 3y agoBXRXBaudax Bio Announces Corporate UpdateGlobeNewswireCompany Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII
- 3y agoBXRXBaudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with InhibitorsGlobeNewswireMALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human
- 3y agoBXRXBaudax Bio to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewswireMALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human
- 3y agoBXRXBaudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common StockGlobeNewswireMALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor ("TCR") therapies utilizing human regulatory
- 3y agoBXRXBaudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewswireMALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T
- 3y agoBXRXBaudax Bio Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireTransformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modest Pace
- 3y agoBXRXBaudax Bio Acquires TeraImmune, Inc.GlobeNewswireTeraImmune, an Advanced Treg Research Company, headed by Yong Chan Kim, Ph D, brings an approved Treg IND to the Strong Development team from Baudax Baudax Bio CEO Gerri Henwood to Serve as CEO of Combined Entity
- 3y agoBXRXBaudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000GlobeNewswireMALVERN, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, today announced additional
- 3y agoBXRXBaudax Bio Announces Date of Reconvened Annual MeetingGlobeNewswireMALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it
- 3y agoBXRXBaudax Bio Reports First Quarter Financial Results and Provides Business UpdateGlobeNewswireAnnounced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent Portfolio Secured $4
- 3y agoBXRXBaudax Bio to Present at the Sidoti Virtual Investor ConferenceGlobeNewswireMALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for hospital and related settings, today announced that Gerri
- 3y agoBXRXBaudax Bio Announces Closing of $4 Million Public OfferingGlobeNewswireMALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for hospital and related settings, today announced
- 3y agoBXRXBaudax Bio Announces Pricing of $4 Million Public OfferingGlobeNewswireMALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for hospital and related settings, today
- 3y agoBXRXBaudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000GlobeNewswireAll Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions at 60 Seconds Results to be Discussed in Key Opinion Leader Webinar Today at 10:00am Eastern Time MALVERN, Pa.,
- 3y agoBXRXBaudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 TrialGlobeNewswireMALVERN, Pa., April 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for hospital and related settings, today announced the Company is
- 3y agoBXRXBaudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000GlobeNewswire41 Subjects Meet Criteria for Good or Excellent Intubation Conditions at 60 Seconds Top Line Results Expected Late April/Early May MALVERN, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the
- 3y agoBXRXBaudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business UpdateGlobeNewswireCompany Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion of Study Enrollment Expected Q1 2023, Top Line Results
- 3y agoBXRXBaudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000GlobeNewswireMALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful outcome of its
- 3y agoBXRXHOTHKALANUWE+1Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030PR NewswireFinancialNewsMedia.com News Commentary Palm Beach, Fla., Dec. 30, 2022 /PRNewswire/ -- According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5
- 3y agoBXRXBaudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing SurgeryGlobeNewswireMALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the initiation of a clinical
- 3y agoBXRXBaudax Bio Announces Closing of $5 Million Public OfferingGlobeNewswireMALVERN, Pa., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for hospital and related settings, today announced
- 3y agoBXRXBaudax Bio Announces Pricing of $5 Million Public OfferingGlobeNewswireMALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of
- 3y agoBXRXBaudax Bio Announces 1-for-40 Reverse Stock SplitGlobeNewswireMALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Company's Board of
- 4y agoBXRXBaudax Bio Reports Third Quarter 2022 Financial Results and Business HighlightsGlobeNewswireBX 1000 Phase II Trial Underway BX 2000 Dose Escalation Study Progressing ANJESO® Vials Sold to End Users Up 16% Third Quarter Year-Over-Year USPTO Issues Note of Allowance for additional Orange Book Listable
- 4y agoBXRXBaudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common StockGlobeNewswireMALVERN, Pa., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that its Board of Directors declared a di
- 4y agoBXRXBaudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare ConferenceGlobeNewswireMALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, w
- 4y agoBXRXBaudax Bio Announces Closing of $6.2 Million Public OfferingGlobeNewswireMALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the closing of its previously announced public of
- 4y agoBXRXBaudax Bio Announces Pricing of $6.2 Million Public OfferingGlobeNewswireMALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of its public offering of an aggregate
- 4y agoBXRXBaudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe painGlobeNewswireMALVERN, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced today that the United States Patent and Trademark Office ("USPTO") has provided a Notice
- 4y agoBXRXBaudax Bio Reports Second Quarter 2022 Financial Results and Business HighlightsGlobeNewswireANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing Complete in the First Cohort of the Phase I BX2000 Study; On Track to Complete Enrollment in Remaining Cohorts by Early 2023 MALVERN, Pa., Aug
- 4y agoBXRXCosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational GrowthBusiness WireExperienced financial executive will build on growth trajectory Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its execut
- 4y agoBXRXBaudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000GlobeNewswireMALVERN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for acute care settings, today announced that the first cohort has been dosed in a First-in-Man, Phase 1 clinical stu
- 4y agoBXRXBaudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences ConferenceGlobeNewswireMALVERN, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, wil
- 4y agoBXRXBaudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireMALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has entered into a definitive agreement with certain
- 4y agoBXRXBaudax Bio Announces Date of Reconvened Annual Meeting of ShareholdersGlobeNewswireMALVERN, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has adjourned its 2022 Annual Meeting of Shareholder
- 4y agoBXRXBaudax Bio Reports First Quarter 2022 Financial Results and Business HighlightsGlobeNewswireANJESO® Net Product Revenue Up 113% Compared to Same Period in Prior Year; Sixth Consecutive Quarter of Demand Growth First Cohort Dosed in Pediatric ANJESO Surgical Study Management to Host Investor Conference Call and Webcast Tomorrow at 8:
- 4y agoBXRXBaudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022GlobeNewswireMALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that it will report first quarter 2022 financial results on Thursday, May 5,
- 4y agoBXRXBaudax Bio to Present at NobleCon18 Investor ConferenceGlobeNewswireMALVERN, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company's President
- 4y agoBXRXBaudax Bio Reports 2021 Fourth Quarter and Annual Financial ResultsGlobeNewswireANJESO End User Demand and Revenue Increases Four Quarters In A Row Neuromuscular Blocking Agents Advancing MALVERN, Pa., March 16, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on comm
- 4y agoBXRXBaudax Bio to Present at the Oppenheimer 32nd Annual Healthcare ConferenceGlobeNewswireMALVERN, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced that Gerri Henwood, the Company's President and C
- 4y agoBXRXBaudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following SurgeryGlobeNewswireMALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced initiation of a clinical study evaluating th
- 4y agoBXRXBaudax Bio Regains Compliance with NASDAQ Listing RequirementsGlobeNewswireMALVERN, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced that the Company received a letter on March 3, 20
- 4y agoBXRXBaudax Bio Announces Seventh Orange Book Listable Patent for ANJESO®GlobeNewswireMALVERN, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that it has secured the issuance of United
- 4y agoBXRXBaudax Bio Announces Pricing of $10.0 Million Public OfferingGlobeNewswireMALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced the pricing of its
- 4y agoBXRXBaudax Bio Announces Proposed Public Offering of SecuritiesGlobeNewswireMALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced it has commenced a
- 4y agoBXRXBaudax Bio Announces 1-for-35 Reverse Stock SplitGlobeNewswireMALVERN, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that the Company's Board of Directors has app
- 4y agoBEKEBXRXEHLPTX+1Thinking about buying stock in Baudax Bio, Standard Lithium, KE Holdings, EHang Holdings, or Leap Therapeutics?PR NewswireNEW YORK, Jan. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BXRX, SLI, BEKE, EH, and LPTX. To
- 4y agoBXRXBaudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceGlobeNewswireMALVERN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company's President a
- 4y agoBXRXBaudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the "Company"), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that the Compensation Commit
- 4y agoBXRXCPGDOGZISIG+1Thinking about buying stock in Insignia Systems, Weibo, Baudax Bio, Crescent Point Energy, or Dogness Corp?PR NewswireNEW YORK, Dec. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISIG, WB, BXRX, CPG, and DOGZ. To